Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients

Gouda Kamel Helal, Magdy Abdelmawgoud Gad, Mohamed Fahmy Abd-Ellah, Mahmoud Saied Eid, Gouda Kamel Helal, Magdy Abdelmawgoud Gad, Mohamed Fahmy Abd-Ellah, Mahmoud Saied Eid

Abstract

The therapeutic effect of pegylated interferon (peg-IFN) alfa-2a combined with ribavirin (RBV) on chronic hepatitis C Egyptian patients is low and further efforts are required to optimize this therapy for achievement of higher rates of virological response. This study aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) in combination with pegylated interferon plus ribavirin on early virological response (EVR) in chronic hepatitis C Egyptian patients. Naïve 120 Egyptian patients with chronic hepatitis C virus infection were divided into two groups. Group 1 have administered the standard of care therapy (pegylated interferon alfa-2a plus ribavirin) for 12 weeks, (n = 60). Group 2 have administered hydroxychloroquine plus standard of care therapy for 12 weeks, (n = 60). Therapeutics included hydroxychloroquine (200 mg) oral twice daily, peginterferon alfa-2a (160 μg) subcutaneous once weekly and oral weight-based ribavirin (1000-1200 mg/day). Baseline characteristics were similar in the two groups. The percentage of early virological response was significantly more in patients given the triple therapy than in patients given the standard of care [54/60 (90%) vs. 43/60 (71.7%); P = 0.011; respectively]. Biochemical response at week 12 was also significantly higher in patients given the triple therapy compared with the standard of care [58/60 (96.7%) vs. 42/60 (70%); P < 0.001; respectively]. Along the study, the observed adverse events were mild and similar across treatment groups. Addition of hydroxychloroquine to pegylated interferon plus ribavirin improves the rate of early virological and biochemical responses in chronic hepatitis C Egyptian patients without an increase in adverse events. J. Med. Virol. 88:2170-2178, 2016. © 2016 Wiley Periodicals, Inc.

Keywords: biochemical response; early virological response; hepatitis C Egyptian patients; hydroxychloroquine; pegylated interferon; ribavirin.

© 2016 Wiley Periodicals, Inc.

References

    1. Abdel‐Razek W, Waked I. 2015. Optimal therapy in genotype 4 chronic hepatitis C: Finally cured? Liver Int 35:27–34.
    1. Aghemo A, Degasperi E, Colombo M. 2013. Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials. Dig Liver Dis 45:1–7.
    1. Ahmed A, Felmlee DJ. 2015. Mechanisms of hepatitis C viral resistance to direct acting antivirals. Viruses 7:6716–6729.
    1. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. 2011. Lysosomotropic agents as HCV entry inhibitors. Virol J 8:163.
    1. Bishop NE. 1998. Examination of potential inhibitors of hepatitis A virus uncoating. Intervirology 41:261–271.
    1. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, Rouillé Y. 2006. Hepatitis C virus entry depends on clathrin‐mediated endocytosis. J Virol 80:6964–6972.
    1. Block JA. 1998. Hydroxychloroquine and retinal safety. Lancet 351:771–771.
    1. Chandramohan M, Vivekanandan S, Sivakumar D, Selvam P. 2007. Chloroquine a novel and versatile anti viral agent with nine prong modes of anti viral actions and postive approach in radical cure of viral hepatitis varieties B and C both acute and chronic forms. Antivir Res 74:A74–A75.
    1. Douam F, Ding Q, Ploss A. 2016. Recent advances in understanding hepatitis C. F1000Res 5:31 (doi: 10.12688/f1000research.7354.1)
    1. El Shishtawy MA, Hassan KH, Ramzy R, Berri F, Mortada M, Nasreddine S, Ezzedine M. 2015. Comparative to xicity study of chloroquine and hydroxychloroquine on adult albino rats. Eur Sci J 1:399–407.
    1. Elefsiniotis I, Vezali E, Mihas C, Saroglou G. 2009. Predictive value of complete and partial early virological response on sustained virological response rates of genotype‐4 chronic hepatitis C patients treated with PEG‐interferon plus ribavirin. Intervirology 52:247–251.
    1. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D. 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa‐2a (40KD)/ribavirin. J Hepatol 43:425–433.
    1. Geamănu A, Popa‐Cherecheanu A, Marinescu B, Geamănu C, Voinea L. 2014. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review. J Med Life 7 322–326.
    1. Guerra J, Garenne M, Mohamed M, Fontanet A. 2012. HCV burden of infection in Egypt: Results from a nationwide survey. J Viral Hepat 19:560–567.
    1. Gutierrez J, Lawitz E, Poordad F. 2015. Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C. J Viral Hepat 22:861–870.
    1. Kamal SM, Nasser IA. 2008. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 47:1371–1383.
    1. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, Esteban R, Abdo AA, Harrison SA, Ibrahim N. 2011. Management of hepatitis C virus genotype 4: Recommendations of an international expert panel. J Hepatol 54:1250–1262.
    1. Kim W, Seo Y, Park S, Lee W, Lee S, Paek S, Cho C, Song H, Kim H. 2001. Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis. Ann Rheum Dis 60:514–517.
    1. Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, Ito S, Buncic RJ. 2001. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358:813–814.
    1. Kouroumalis E, Koskinas J. 1986. Treatment of chronic active hepatitis B (CAH B) with chloroquine: A preliminary report. Ann Acad Med Singapore 15:149–152.
    1. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS. 2014. Phase 2b trial of interferon‐free therapy for hepatitis C virus genotype 1. N Engl J Med 370:222–232.
    1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M‐H, Albrecht JK. 2001. Peginterferon alfa‐2b plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958–965.
    1. Meertens L, Bertaux C, Dragic T. 2006. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin‐coated vesicles. J Virol 80:11571–11578.
    1. Michaelides M, Stover NB, Francis PJ, Weleber RG. 2011. Retinal toxicity associated with hydroxychloroquine and chloroquine: Risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol 129:30–39.
    1. Mohamed AA, Elbedewy TA, El‐Serafy M, Ahmed W, El Din ZA. 2015. Hepatitis C virus: A global view. World J Hepatol 7:2676.
    1. Muir AJ, Bornstein JD, Killenberg PG. 2004. Peginterferon alfa‐2b and ribavirin for the treatment of chronic hepatitis C in blacks and non‐Hispanic whites. N Engl J Med 350:2265–2271.
    1. National Institute of Allergy and Infectious Disease. Website:
    1. O'Neill PM, Bray PG, Hawley SR, Ward SA, Park BK. 1998. 4‐Aminoquinolines—Past, present, and future; A chemical perspective. Pharmacol Ther 77:29–58.
    1. Offensperger W‐B, Offensperger S, Walter E, Blum HE, Gerok W. 1991. Inhibition of duck hepatitis B virus infection by lysosomotropic agents. Virology 183:415–418.
    1. Paton N, Aboulhab J. 2005. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV‐infected patients with low viral load: Safety, efficacy and resistance profile after 144 weeks. HIV Med 6:13–20.
    1. Pearlman BL, Ehleben C, Saifee S. 2007. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1‐infected slow responders. Hepatology 46:1688–1694.
    1. Randolph VB, Winkler G, Stollar V. 1990. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174:450–458.
    1. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB. 2014. Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10:1391–1402.
    1. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. 2000. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 182:698–707.
    1. Rolain J‐M, Colson P, Raoult D. 2007. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30:297–308.
    1. Ruiz‐Irastorza G, Ramos‐Casals M, Brito‐Zeron P, Khamashta MA. 2008. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 69:20–28.
    1. Sarrazin C. 2016. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486–504.
    1. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. 2003. Effects of chloroquine on viral infections: An old drug against today's diseases. Lancet Infect Dis 3:722–727.
    1. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. 2006. New insights into the antiviral effects of chloroquine. Lancet Infect Diseases 6:67–69.
    1. Schaefer M, Heinz A, Backmund M. 2004. Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? Addiction 99:1167–1175.
    1. Schuppan D, Schöpper H, Oesterling C, Somasundaram R, Stoelzel U, Boigk G, Riecken E. 1998. Chloroquine (CQ) can induce a biochemical response in patients with chronic hepatitis C. J Hepatol 28:199.
    1. Shehab HM, Elbaz TM, Deraz DM. 2014. Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial. Liver Int 34:259–265.
    1. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962–973.
    1. Sundelin SP, Terman A. 2002. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. Apmis 110:481–489.
    1. Thomé R, Lopes SCP, Costa FTM, Verinaud L. 2013. Chloroquine: Modes of action of an undervalued drug. Immunol Lett 153:50–57.
    1. Wantuck J, Ahmed A, Nguyen M. 2014. Review article: The epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 39:137–147.
    1. Wozniacka A, Lesiak A, Narbutt J, Kobos J, Pavel S, Sysa‐Jedrzejowska A. 2007. Chloroquine treatment reduces the number of cutaneous HLA‐DR+ and CD1a+ cells in patients with systemic lupus erythematosus. Lupus 16:89–94.
    1. Zeuzem S. 2008. Interferon‐based therapy for chronic hepatitis C: Current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 5:610–622.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir